DGDanielle Graham

Danielle Graham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danielle Graham has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics

    by Amanda J. Guise, Kyle L. Ferber, Damon Young, Amanda L. Edwards, Somayeh Sabouri, Kyle B. Fraser, Eric Milliman, Edward D. Plowey, Jad Zoghbi, Stephanie M. Fradette, et al.

  • Open Access

    Biomarker development for the tau therapeutic landscape

    by Danielle Graham

    The hallmark neuropathological changes associated with Alzheimer's disease (AD) include extracellular amyloid beta plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Because NFTs are strongly associated with clinical impairment, multiple therapeutic programs focused on reducing tau pathology have been initiated, necessitating the development of biomarkers specific to tau pathology. Current tau blood‐based biomarkers (e.g., phosphorylated tau 181 [p‐tau181] and 217 [p‐tau217]) are more closely associated with amyloid pathology than tau pathology and may not allow specific assessment of the presence of, or therapeutic impact on, neuropathological tau. BIIB080 is a microtubule associated protein tau ( MAPT )–targeting antisense oligonucleotide that reduces production of tau protein. Exploratory analysis from the BIIB080 Phase 1b trial (NCT03186989) demonstrated that BIIB080 treatment was associated with a dose‐dependent and sustained reduction in soluble tau protein in cerebrospinal fluid (CSF), and exploratory analysis evaluating the change in soluble p ‐tau in plasma is in progress. Moreover, BIIB080 impacted aggregated parenchymal tau pathology, as measured by tau positron emission tomography, demonstrating a reduction of tau pathology from baseline across all brain composites assessed at the end of the long‐term extension. These data were the first to show this magnitude of treatment response on this pathological hallmark of AD. The ongoing Phase 2 CELIA trial (NCT05399888) will further evaluate impacts of BIIB080 on these biomarkers, as well as the safety and efficacy of BIIB080 in a larger and broader AD population. Emerging candidates for tau‐specific biomarkers include p ‐tau205 and a portion of the microtubule binding region of tau containing the residue 243 (MTBR‐tau243). Evaluation of the impact of BIIB080 on these measures and other novel biomarkers of tau pathology is ongoing. However, these biomarkers are currently measured in CSF only, and evidence for their use as treatment‐response measures is limited. Based on emerging tau biomarker advances and biomarker results from BIIB080, this presentation will provide future directions on the use and importance of tau biomarkers for development of therapies targeting tau.

  • Open Access

    Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

    by Tracy A. Cole, Hien Zhao, Timothy J. Collier, Ivette M Sandoval, Caryl E. Sortwell, Kathy Steece-Collier, Brian F. Daley, Alix Booms, Jack Lipton, Mackenzie Welch, et al.

    Parkinson’s disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding alpha-synuclein protein (aSyn), either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent pre-formed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the non-human primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that by inhibiting production of aSyn it may be possible to reverse established pathology and thus supports the development of SNCA ASOs as a potentially disease modifying therapy for PD and related synucleinopathies. Summary: Antisense oligonucleotides designed against SNCA , which are progressing to the clinic, have the potential to be a disease modifying therapeutic for Parkinson’s disease patients.


  • Open Access

    Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression

    by Brit Mollenhauer, Mohammed Dakna, Tzu-Ying Liu, Douglas Galasko, Tatiana Foroud, Henrik Zetterberg, Sebastian Schade, Roland G. Gera, Wenting Wang, Feng Gao, et al.

    Background Alterations in neurofilament light chain (NfL), reflecting axonal damage, have been proposed as a biomarker for neurological disorders including Parkinson’s disease (PD). Methods We measured NfL concentrations by immunoassay in (1) a set of longitudinal CSF samples from 82 PD, 14 other neurodegenerative disorders (OND), and 53 healthy controls (HC); (2) A cross-sectional cohort with paired CSF and serum samples from subjects with 151 PD, 344 OND, and 20 HC, and (3a) a large longitudinal validation cohort with serum samples from 375 PD, 178 HC, and 57 prodromal Lewy Body disorder with hyposmia or isolated REM sleep behaviour disorder (iRBD), (3b) 216 symptomatic and 298 asymptomatic LRRK2, GBA, and SNCA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI). Mean differences in serum NfL levels between diagnostic groups, and correlation with motor signs, cognitive measures and dopamine transporter imaging, were assessed. Linear mixed effects models were used to assess longitudinal changes in log10 (NfL) in relation to demographic, clinical, and imaging variables. Findings In the longitudinal cohort (1) NfL in CSF increased over time and was significantly positively correlated with MDS-UPDRS III motor and total scores in the PD group (p=0·0231 and 0·0081). In the cross-sectional cohort (2) the paired CSF and serum NfL samples were highly correlated (Spearman’s rank ). In the large validation cohort (3a) mean baseline serum NfL was higher in PD (13 ±7·2pg/ml), hyposmics (15±15·1pg/ml), and iRBD (17±8pg/ml) compared with HC (12±6·7pg/ml) but was highest in the seven OND cases (18±7pg/ml). In the genetic cohort (3b), serum NfL levels were lower in asymptomatic than in symptomatic mutation carriers. There was a significant (age-adjusted) longitudinal increase in serum NfL in PD compared with HC. Serum NfL values were significantly positively associated with longitudinal MDS-UPDRS motor and total scores, as well as age. Interpretation We identified NfL as the first blood-based PD progression biomarker. NfL levels in serum samples are increased in PD compared to HC, increase significantly over time in PD, and correlate with a clinical measure of disease severity. Although the specificity of NfL in PD is low and additional, more specific biomarkers are needed, serum NfL is the first blood-based biomarker candidate that could support disease stratification (PD vs. OND), track clinical progression, and might be used to assess responsiveness to neuroprotective treatments.


  • Open Access

    Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration

    by Qin Wang, Luisette Delva, Paul H. Weinreb, Robert B. Pepinsky, Danielle Graham, Elvana Veizaj, Anne E. Cheung, Weiping Chen, Ivan Nestorov, Ellen Rohde, et al.

    Many studies have focused on the challenges of small molecule uptake across the blood–brain barrier, whereas few in-depth studies have assessed the challenges with the uptake of antibodies into the central nervous system (CNS). In drug development, cerebrospinal fluid (CSF) sampling is routinely used as a surrogate for assessing CNS drug exposure and biomarker levels. In this report, we have studied the kinetic correlation between CSF and serum drug concentration–time profiles for five humanized monoclonal antibodies in rats and cynomolgus monkeys and analyzed factors that affect their CSF exposure. Upon intravenous (IV) bolus injection, antibodies entered the CNS slowly and reached maximum CSF concentration ( CSF T max ) in one to several days in both rats and monkeys. Antibody serum and CSF concentration–time curves converged until they became parallel after CSF T max was reached. Antibody half-lives in CSF ( CSF t ½ ) approximated their serum half-lives ( serum t ½ ). Although the intended targets of these antibodies were different, the steady-state CSF to serum concentration ratios were similar at 0.1–0.2% in both species. Independent of antibody target and serum concentration, CSF-to-serum concentration ratios for individual monkeys ranged by up to tenfold from 0.03 to 0.3%. Upon systemic administration, average antibodies CSF-to-serum concentration ratios in rats and monkeys were 0.1–0.2%. The CSF t ½ of the antibodies was largely determined by their long systemic t ½ ( systemic t ½ ).